COVID Clinical Trial
Official title:
The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice
This is a retrospective analytical study conducted at Vascular and Endovascular surgery Department, Mansoura University Hospital, including all patients admitted at the two periods first six months of 2019 and 2020.To demonstrate the effect of COVID-19 pandemic on the practice of emergency vascular surgery and critical limb threatening ischemia interventions by comparison two periods first six months of 2019 and 2020.
INTRODUCTION:
The novel coronavirus pneumonia (COVID-19) pandemic has affected the globe, with Italy
leading many reports of the incidence and mortalities. Recently reported studies have
described the clinical characteristics and overall outcomes of patients with COVID-19 and the
effects of treating these patients on the healthcare system.Two studies have reported
associated coagulopathy disorders. These reports have highlighted the presence of a
coexisting hypercoagulable state in patients with COVID-19, which might be associated with
higher mortality.
The COVID-19 pandemic has had many impacts, both seen and unforeseen, all over the world. As
expected, elective endovascular procedures have been halted, with a significant decrease in
urgent/emergent procedures. This could reflect an understandable unwillingness on the part of
patients who continue to self-isolate at home to come in for treatments, including those with
Critical limb threatening ischemia. Also impacts on the supply chain side of performing
interventions, had been reported, it is challenging to be in the middle of a complex CLTI
(Critical limb threatening ischemia) case and request a routine device only to find out it is
unavailable.
Aim of the work Evaluation the impact of COVID-19 pandemic on emergency vascular practice and
critical limb ischemia.
Outcome
Primary outcomes:
- Frequencies of patients admitted at the Vascular.
- Predisposing Factors.
- Number of ICU admission.
Secondary outcomes:
• Mortality rates
Patients and methods Study location: The study will be conducted at the department of
vascular surgery in Mansoura university hospitals Type of study: Observational analytical
study Study duration: 2019-2020 Sample size: It will include all patients presented to our
department at the first 6 months of 2019 and first 6 months of 2020. sample size will be
140-400 patients Inclusion criteria: all patients admitted to our department at that periods
Exclusion criteria
1. Patients can't give consent (unconscious).
2. Those with mental or behavioral disorders will be excluded. Consent: Patients after
signing informed consent that possible complication from the procedure ought to happen
and what are the alternatives.
Data collection:
- All patients with complete medical records available will be documented
- Each patient's record will be analyzed to determine preexisting illnesses, admitting
symptoms (including length of time to accessing medical care), admission physical
findings, laboratory and results.
- Also, the type and duration of antibiotic therapy, the frequency and type of operative
procedures performed and subsequent complications.
- Supporting modalities such as dialysis, blood product transfusion, and mechanical
ventilation will be were reviewed.
- Each patient's premorbid medical profile, condition at admission, and subsequent
treatment also will be analyzed to assess effect on mortality and development of
complications.
- Standard treatment after admission including cardiovascular stabilization and assessment
of extent of infection. Broad-spectrum antibiotics were administered to cover
gram-positive cocci, gram-negative enteric rods, and anaerobic flora will be also
reported.
- The procedure of Surgical Management will be described.
Statistical analysis
· The data will be analyzed using Statistical Package for the Social Sciences. The numerical
outcomes e.g. age is calculated as median. Gender will be recorded as frequency and
percentage. Chi Square test is applied to assess the association of various parameters. The
results will be considered statistically significant if the p-value is found to be less than
or equal to 0.05. To assess possible risk factors for mortality, univariate analyses will be
completed initially to aid in determining the variables that should be included in a stepwise
logistic regression model.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |